NCT05259917CompletedPhase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II
KalVista Pharmaceuticals, Ltd.3 sites in 3 countries136 target enrollmentStarted: February 22, 2022Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 136
- Locations
- 3
- Primary Endpoint
- Time to Beginning of Symptom Relief Patient Global Impression of Change (PGI-C)
Study Overview
Brief Summary
This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult Patients
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 12 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female patients 12 years of age and older.
- •Confirmed diagnosis of HAE type I or II at any time in the medical history.
- •Patient has access to and ability to use conventional on-demand treatment for HAE attacks.
- •If a patient is receiving long-term prophylactic treatment with one of the protocol-allowed therapies, they must be on a stable dose and regimen for at least 3 months prior to the Screening Visit (except for danazol, which requires a stable dose and regimen for 6 months prior to the Screening Visit). Patient must be willing to remain on a stable dose and regimen for the duration of the trial.
- •Patient's last dose of attenuated androgens other than danazol was at least 28 days prior to randomization.
- •has had at least 2 documented HAE attacks within 3 months prior to screening or randomization; or
- •is a completer of the KVD824-201 trial within 3 months prior to randomization and meets all other entry criteria to enroll in KVD900-301
- •Patients must meet the contraception requirements.
- •Patients must be able to swallow trial tablets whole.
- •Patients, as assessed by the Investigator, must be able to appropriately receive and store IMP, and be able to read, understand, and complete the electronic diary (eDiary).
- •Investigator believes that the patient is willing and able to adhere to all protocol requirements.
- •Patient provides signed informed consent or assent (when applicable). A parent or legally authorized representative (LAR) must also provide signed informed consent when required.
Exclusion Criteria
- •Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1-inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.
- •A clinically significant history of poor response to bradykinin receptor 2 (BR2) blocker, C1-INH therapy or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator.
- •Use of angiotensin-converting enzyme (ACE) inhibitors after the Screening Visit or within 7 days prior to randomization.
- •Any estrogen containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the Screening Visit.
- •Patients who require sustained use of strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers.
- •Inadequate organ function, including but not limited to:
- •Alanine aminotransferase (ALT) >2x upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) >2x ULN
- •Bilirubin direct >1.25x ULN
- •International normalized ratio (INR) >1.2
- •Clinically significant hepatic impairment defined as a Child-Pugh B or C
- •Any clinically significant comorbidity or systemic dysfunction, which in the opinion of the Investigator, would jeopardize the safety of the patient by participating in the trial.
- •History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator.
- •Known hypersensitivity to KVD900 or placebo or to any of the excipients.
- •Prior participation in trial KVD900-
- •Participation in any gene therapy treatment or trial for HAE.
- •Participation in any interventional investigational clinical trial (with the exception of KVD824-201), including an investigational COVID-19 vaccine trial, within 4 weeks of the last dosing of investigational drug prior to screening.
- •Any pregnant or breastfeeding patient.
Arms & Interventions
Placebo
Placebo Comparator
Intervention: Placebo (Drug)
KVD900 600 mg
Experimental
Intervention: KVD900 600 mg (Drug)
KVD900 300 mg
Experimental
Intervention: KVD900 300 mg (Drug)
Outcomes
Primary Outcomes
Time to Beginning of Symptom Relief Patient Global Impression of Change (PGI-C)
Time Frame: Within 12 hours of the first investigational medicinal product (IMP) administration.
The analysis of time to the beginning of symptom relief defined as at least "a little better" (2 time points in a row) on the PGI-C within 12 hours of the first IMP administration using the Gehan score transformation test for Full Analysis Set (FAS). Attacks were treated as right-censored at 12 hours if they did not achieve beginning of symptom relief defined by PGI-C as at least "a little better" (2 time points in a row) or received conventional attack treatment prior to time-to-event within 12 hours of the first IMP administration. When an endpoint result was non-evaluable (NE) within 12 hours, if the event did occur, the event must have occurred \>12 hours following study drug.
Secondary Outcomes
- Time to First Incidence of Decrease From Baseline Patient Global Impression of Severity (PGI-S) (2 Time Points in a Row)(Within 12 hours of the first IMP administration.)
- Time to Complete HAE Attack Resolution (PGI-S)(Within 24 hours of the first IMP administration.)
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Terminated
Phase 3
Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial FibrillationParoxysmal Atrial FibrillationNCT05039359InCarda Therapeutics, Inc.54
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLCTreatment-naive Advanced Non-small Cell Lung CancerNCT03856411Shanghai Junshi Bioscience Co., Ltd.465
Recruiting
Phase 3
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical CancerMETASTATIC CERVICAL CANCERNCT05446883Qilu Pharmaceutical Co., Ltd.498
Completed
Phase 3
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCancerNCT00538850INSYS Therapeutics Inc130
Active, not recruiting
Phase 3
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationCarcinoma, Non-Small-Cell LungNCT03833154AstraZeneca724